Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Ultragenyx Pharmaceutical Inc. price momentum is very positive. Ultragenyx Pharmaceutical Inc. is not very popular among insiders. Ultragenyx Pharmaceutical Inc. is a mediocre stock to choose.
Log in to see more information.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification,...
RARE Fundamental Data by TradingView

News

Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $87.43
Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $87.43

Zolmax Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have received a consensus rating of "Moderate Buy" from the fourteen analysts that are covering the stock, MarketBeat.com...\n more…

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Brokerages

Ticker Report Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, Marketbeat Ratings...\n more…

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Simply Wall St David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...\n more…

Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Adial Pharmaceuticals (NASDAQ:ADIL)
Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Adial Pharmaceuticals (NASDAQ:ADIL)

Zolmax Adial Pharmaceuticals (NASDAQ:ADIL - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) are both medical companies, but which is the superior business? We will contrast...\n more…

Pinnacle Associates Ltd. Buys 41,633 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Pinnacle Associates Ltd. Buys 41,633 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Ticker Report Pinnacle Associates Ltd. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 34.9% during the 2nd quarter, Holdings Channel reports. The fund owned 161,020...\n more…

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Wealth Enhancement Advisory Services LLC
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Wealth Enhancement Advisory Services LLC

Ticker Report Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.3% in the 2nd quarter, according to the company in its most...\n more…